GENETIC TECHNOLOGIES ADR REP 3 (GENE)

Genetic Tech Sp ADR 

Valor: 26683707 / Symbol: GENE
  • 0.850 USD
  • 0.00% 0.000
  • 16.02.2019 02:00:00
348 posts / 0 new
Letzter Beitrag
Lorenz
Bild des Benutzers Lorenz
Offline
Zuletzt online: 04.02.2019
Mitglied seit: 16.04.2010
Kommentare: 1'410
Wer hat News

Heute reges Treiben bei GENE, beinahe + 8%, beachtliches Volumen für diesen Titel zurzeit, was ist im Busch?

Aktuell 1.27, Höchst heute 1.32. Geht es wieder um eine Übernahme wie vor den Feiertagen?

Simona
Bild des Benutzers Simona
Offline
Zuletzt online: 06.11.2018
Mitglied seit: 19.05.2006
Kommentare: 1'358
Ja, sehr gut und ich hoffe

Ja, sehr gut und ich hoffe auf eine rege Stimmbeteiligung in der Sache und gutes Gelingen an der GV vom 31. Januar.

Gruss, Simona

Emil
Bild des Benutzers Emil
Offline
Zuletzt online: 31.01.2019
Mitglied seit: 28.09.2007
Kommentare: 3'108
GENE

Emil

Simona
Bild des Benutzers Simona
Offline
Zuletzt online: 06.11.2018
Mitglied seit: 19.05.2006
Kommentare: 1'358
GENE zu einem schönen Kurs

GENE zu einem schönen Kurs weiterhin existieren lassen wäre noch besser. Ich möchte die Aktien nicht verschenken. Wink  Smile

Gruss, Simona

Emil
Bild des Benutzers Emil
Offline
Zuletzt online: 31.01.2019
Mitglied seit: 28.09.2007
Kommentare: 3'108
ÜBERNAHME

@Lorenz

Es schaut ganz danach aus. Hoffe natürlich auf einen superschönen Kurs... Smile  Dirol

(Sorry für die verspätete Antwort, hier war das Forum offenbar gestört).

Emil

Lorenz
Bild des Benutzers Lorenz
Offline
Zuletzt online: 04.02.2019
Mitglied seit: 16.04.2010
Kommentare: 1'410
 Übernahme?

 

Wird das nun eine Übernahme?

 

Genetic Tech up 11% on takeover interest

Dec. 12, 2017 11:58 AM ET|By: , SA News Editor

Thinly traded nano cap Genetic Technologies (GENE +10.7%) is up more than double normal volume after it announced that potential suitors made presentations to the Chairman and CEO in late November.

In August, it announced that it had initiated a review of strategic alternatives, including an outright sale of the company.

Previously: Genetic Technologies announces comprehensive review of strategic alternatives (Aug. 25)

See all stocks on the move »

SeekingAlpha

1,065 people get GENE breaking news and analysis by email alert

 

EX-99.1 2 a17-28325_1ex99d1.htm EX-99.1

Exhibit 99.1

 

 

ASX ANNOUNCEMENT

12 December 2017

 

Genetic Technologies Provides Update on Strategic Review Initiative

 

Melbourne, Australia, 12 December 2017: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”), a molecular diagnostics company focused on cancer risk assessment, and provider of BREVAGenplus®, a first-in-class, clinically validated risk assessment test for non-hereditary breast cancer, is pleased to report that it has entered an important stage of the Company’s strategic review which was announced to the market on 25 August 2017.

 

At that time, the Company announced the engagement of Roth Capital Partners, LLC (Roth) a U.S. based corporate advisory firm to launch a comprehensive strategic review initiative with a clear mandate to explore a wide range of possible strategic opportunities for the Company and its assets - designed to maximise near and long-term value for the shareholders.

 

Since their appointment, Roth has conducted a confidential market out-reach program to identify potential interested parties. Following what was an intensive and systematic screening process, a target short list was prepared, with the shortlisted targets invited to present to the Company’s Chairman and Chief Executive Officer. The presentations took place in New York during the week commencing 27 November 2017; each party having expressed significant interest in the Company and its assets.

 

The Company remains in active discussions with multiple parties regarding a potential transaction(s) as those short listed interested parties now continue their due diligence. The Board remains committed to the strategic review and will carefully consider all alternatives and make a decision that reflects the best interest of all shareholders.

 

However, as advised to the market, the Company is in receipt of a Section 249D notification requesting a shareholder meeting and with proposed resolutions for the removal of current Board members: Dr. Malcolm R Brandon, Mr. Grahame Leonard and Mr. Eutillio Buccilli and appointment of nominees by the requisitioning shareholders. Accordingly there can be no assurance as to whether or not any transaction arising out of the Roth strategic review will take place, the structure of any such potential transaction, or the ultimate timing. In part this may depend upon the results of the shareholder meeting to be convened to consider the change in the Company’s board composition.

 

Genetic Technologies Limited · Website: www.gtglabs.com · Email: info@gtglabs.com ABN 17 009 212 328

Registered Office · 60-66 Hanover Street Fitzroy Victoria 3065 Australia · Postal Address P.O. Box 115 Fitzroy Victoria 3065 Australia Phone +61 3 8412 7000 · Fax +61 3 8412 7040

 

 

 

FOR FURTHER INFORMATION PLEASE CONTACT

 

Mr. Eutillio Buccilli

Jason Wong (USA)

Executive Director & Chief Executive Officer

Blueprint Life Science Group

Genetic Technologies Limited

+ 1 (415) 375 3340, Ext. 4

+ 61 3 8412 7050

 

 

 

Eric Cheng (USA)

 

Managing Director

 

Roth Capital Partners

 

+ 1 (646) 358 1901

 

 

About Genetic Technologies Limited

 

Genetic Technologies is a molecular diagnostics company that offers cancer predictive testing and assessment tools to help physicians proactively manage patient health. The Company’s lead product, BREVAGenplus®, is a clinically validated risk assessment test for non-hereditary breast cancer and is first in its class. BREVAGenplus is designed to facilitate better informed decisions about breast cancer screening and preventive treatment plans, and is directed towards women aged 35 years or above, who have not had breast cancer and have one or more risk factors for developing breast cancer.

 

The Company markets BREVAGenplus, through its U.S. subsidiary Phenogen Sciences Inc., to healthcare professionals in comprehensive breast health care and imaging centres, as well as to obstetricians/gynaecologists (OBGYNs) and breast cancer risk assessment specialists (such as breast surgeons). For more information, please visit www.brevagenplus.com and www.phenogensciences.com.

 

Genetic Technologies is developing a pipeline of risk assessment products including a novel colorectal cancer (CRC) test. For more information, please visit www.gtgcorporate.com

 

About Roth Capital Partners

 

ROTH Capital Partners, LLC (ROTH), is a relationship-driven investment bank focused on serving emerging growth companies and their investors. As a full-service investment bank, ROTH provides capital raising, M&A advisory, analytical research, trading, market-making services and corporate access. Headquartered in Newport Beach, California, ROTH is privately-held and employee owned, and maintains offices throughout the U.S. For more information on ROTH, please visit www.roth.com.

 

Safe Harbor Statement

 

Any statements in this press release that relate to the Company’s expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act. The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Company’s actual results may differ materially from expected results. Additional risks associated with Genetic Technologies’ business can be found in its periodic filings with the SEC.

 

 

Lorenz
Bild des Benutzers Lorenz
Offline
Zuletzt online: 04.02.2019
Mitglied seit: 16.04.2010
Kommentare: 1'410
Info heute:
Lorenz
Bild des Benutzers Lorenz
Offline
Zuletzt online: 04.02.2019
Mitglied seit: 16.04.2010
Kommentare: 1'410
Info:
Simona
Bild des Benutzers Simona
Offline
Zuletzt online: 06.11.2018
Mitglied seit: 19.05.2006
Kommentare: 1'358
Q1-2017/18 / Quartalsbericht Ende September 2017
Lorenz
Bild des Benutzers Lorenz
Offline
Zuletzt online: 04.02.2019
Mitglied seit: 16.04.2010
Kommentare: 1'410
Geschäftsbericht 2017

Info

Geschäftsbericht: und Generalversammlung

https://www.sec.gov/Archives/edgar/data/1166272/000110465917063197/a17-24326_1ex99d1.htm:

Wann sehen wir die Quartalszahlen?

 

 

 

Lorenz
Bild des Benutzers Lorenz
Offline
Zuletzt online: 04.02.2019
Mitglied seit: 16.04.2010
Kommentare: 1'410
Hier noch vom 21.09.17 News
Simona
Bild des Benutzers Simona
Offline
Zuletzt online: 06.11.2018
Mitglied seit: 19.05.2006
Kommentare: 1'358
@Lorenz
Lorenz
Bild des Benutzers Lorenz
Offline
Zuletzt online: 04.02.2019
Mitglied seit: 16.04.2010
Kommentare: 1'410
Q4 und Jahreszahlen

Besser als gedacht: Mehr Tests im Quartal, Kosten reduziert, bessere Aussichten...

http://news.iguana2.com/macquaries/ASX/GTG/474017

Vielleicht werden wir mal noch profitabel?

Lorenz
Bild des Benutzers Lorenz
Offline
Zuletzt online: 04.02.2019
Mitglied seit: 16.04.2010
Kommentare: 1'410
@ GENE 

@ GENE  Help

Welchem Umstand verdanken wir diesen Kursrückgang? Ist das Euer Sommer-Sonderverkauf?! Wir haben Sommer hier. Recht unterschiedliches T-Shirt und Long-Shirt-Wetter, aber ohne Reverse-Split.-

Holt gefälligst den Kurs rauf. Wir machen keine Repetition.

Emil
Bild des Benutzers Emil
Offline
Zuletzt online: 31.01.2019
Mitglied seit: 28.09.2007
Kommentare: 3'108

Emil

Lorenz
Bild des Benutzers Lorenz
Offline
Zuletzt online: 04.02.2019
Mitglied seit: 16.04.2010
Kommentare: 1'410
Info Quarterly Results per Dezember 2018

Hier fehlen einige Beiträge wie mir scheint.*shok*

Info, ist etwas viel Text, aber positiv*smile*

https://www.asx.com.au/asxpdf/20190130/pdf/4426371ddml231.pdf

 

Emil
Bild des Benutzers Emil
Offline
Zuletzt online: 31.01.2019
Mitglied seit: 28.09.2007
Kommentare: 3'108
Results und verlorene Beiträge

Betr. verlorene Beiträge- Danke für die Info. Von dir Lorenz kann man im alten Forum noch einen Beitrag sehen hier vom 5. Jan. 2018. Da scheint schon einiges zu fehlen (?!).

Emil

Seiten